Browse News
Filter News
Found 346 articles
-
InMode to Report First Quarter 2024 Financial Results and Hold Conference Call May 2, 2024
4/9/2024
InMode Ltd. announced today that it expects to release its financial results for the first quarter of 2024 before the Nasdaq market opens on Thursday, May 2, 2024.
-
InMode to Present at Upcoming Investor Conferences and Events - April 3, 2024
4/3/2024
InMode Ltd. today announced the participation at the following investor conferences and events in April and May.
-
Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update
3/13/2024
Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.
-
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024
3/6/2024
Spero Therapeutics, Inc. today announced that it will host a conference call and live audio webcast on Wednesday, March 13, 2024 at 4:30 p.m. ET to report its fourth quarter and full year financial results.
-
InMode to Present at March Investor Conferences and Events
3/4/2024
InMode Ltd. today announced the participation at the following investor conferences and events in March.
-
Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections
2/28/2024
Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it has received clearance by the U.S. Food and Drug Administration (FDA) for its investigational new drug (IND) application, to evaluate SPR206 in a Phase 2 clinical study.
-
Spero Therapeutics to Present at Cowen’s 44th Annual Healthcare Conference
2/26/2024
Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero) today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the Cowen 44th Annual Healthcare Conference.
-
InMode Reports Fourth Quarter and Full Year 2023 Financial Results; Quarterly Revenue of $126.8M and Record Full Year Revenue of $492M
2/13/2024
InMode Ltd., a leading global provider of innovative medical technologies, announced its consolidated financial results for the fourth quarter and full year ended December 31, 2023.
-
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 31, 2024
1/31/2024
Spero Therapeutics, Inc. announced that on January 29, 2024, the Compensation Committee of Spero’s Board of Directors approved the grant of an aggregate of 50,000 restricted stock unit awards to a new employee under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended, or the 2019 Inducement Plan.
-
InMode to Report Fourth Quarter & Full Year 2023 Financial Results and Hold Conference Call on Feb. 13, 2024
1/16/2024
InMode Ltd. announced today that it expects to release its financial results for the fourth quarter and full year 2023 before the Nasdaq market opens on Tuesday, February 13, 2024.
-
Spero Therapeutics Provides Corporate Update and 2024 Outlook
1/5/2024
Spero Therapeutics, Inc. today provided a corporate update highlighting its recent accomplishments and anticipated milestones for 2024.
-
Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections
1/2/2024
Spero Therapeutics, Inc. announced the first patient, first visit for PIVOT-PO, a global pivotal Phase 3 clinical trial of tebipenem HBr in patients with complicated urinary tract infections, including acute pyelonephritis.
-
Spero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business Update
11/13/2023
Spero Therapeutics, Inc., a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant bacterial infections, announced financial results for the third quarter ended September 30, 2023, and provided a business update.
-
Takeda’s ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
11/9/2023
Takeda announced that the U.S. Food and Drug Administration has approved ADZYNMA for the prophylactic and on-demand treatment of adult and pediatric patients with congenital thrombotic thrombocytopenic purpura.
-
Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023
11/6/2023
Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it will host a conference call and live audio webcast on Monday, November 13, 2023 at 4:30 p.m. ET to report its third quarter 2023 financial results and provide an update on its business and pipeline.
-
InMode Reports Third Quarter 2023 Financial Results; Quarterly Revenue of $123.1M Represents 2% Year-Over-Year Growth
11/2/2023
InMode Ltd., a leading global provider of innovative medical technologies, announced its consolidated financial results for the third quarter ended September 30, 2023.
-
Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer
11/1/2023
Spero Therapeutics, Inc. announced the appointment of Esther Rajavelu as Chief Financial Officer and Chief Business Officer.
-
Spero Therapeutics to Present at Upcoming November 2023 Investor Conferences
11/1/2023
Spero Therapeutics, Inc. announced that Sath Shukla, President and Chief Executive Officer, will be available for one-on-one meetings at the Truist Securities BioPharma Symposium, to be held at the Lotte New York Palace in New York, NY, on November 8-9, 2023 and will present and be available for one-on-one meetings at the 6th Annual Evercore ISI HealthCONx Conference to be held at the Kimpton EPIC Miami Hotel in Miami, FL, on November 28-30, 2023.
-
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 31, 2023
10/31/2023
Spero Therapeutics, Inc. announced that on October 27, 2023, the Compensation Committee of Spero’s Board of Directors approved the grant of an aggregate of 65,000 restricted stock unit awards to a new employee under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended, or the 2019 Inducement Plan.
-
InMode Expects Third Quarter 2023 Revenue Between $122.8M-$123.0M, Lowering Full-Year 2023 Revenue Guidance to $500M-$510M vs. Original Estimates of $530M-$540M
10/12/2023
InMode Ltd., a leading global provider of innovative medical technologies, announced that it expects to release its financial results for the third quarter of 2023 before the Nasdaq market opens on Thursday, Nov. 2, 2023.